Interleukin-2-induced antinociception in morphine-insensitive rats

Acta Pharmacol Sin. 2002 Nov;23(11):981-4.

Abstract

Aim: To investigate interleukin-2-induced antinociception in morphine-insensitive rats.

Methods: Paw withdrawal latencies (PWL) to noxious radiant heat were taken as the measurement of pain threshold.

Results: Intraplantar injection of human recombinant interleukin-2 (1.5 x10(4) U) significantly increased PWL in normal rats. PWL was also markedly increased by IL-2 in 45-d-post-complete Freund's adjuvant (CFA)-treated rats, which have been proven morphine-insensitive. IL-2-induced antinociception in CFA-treated rats were significantly lower than that in normal rats. IL-2-induced antinociception was partially blocked by naloxone (1 mg/kg, ip) in normal rats but remained unchanged in CFA group.

Conclusion: IL-2-induced antinociception is partially mediated by mu-opioid receptors. Therapeutic applications of IL-2 may also be expanded to relieve morphine-insensitive pain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Animals
  • Drug Tolerance
  • Freund's Adjuvant / pharmacology
  • Interleukin-2 / pharmacology*
  • Interleukin-2 / therapeutic use
  • Male
  • Morphine / adverse effects*
  • Naloxone / pharmacology*
  • Pain / drug therapy
  • Pain Threshold / drug effects*
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Receptors, Opioid, mu / physiology*
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use

Substances

  • Analgesics
  • Interleukin-2
  • Receptors, Opioid, mu
  • Recombinant Proteins
  • Naloxone
  • Morphine
  • Freund's Adjuvant